Procter & Gamble Health Ltd

As of 07-Nov, Procter & Gamble Health Ltd's stock price is 5,840.00, down 2.48% and underperforming against its sector and moving averages. Despite a strong return on equity and increased investor interest, the stock has struggled recently, reflecting a challenging short-term environment.

P & G Health Ltd experienced a decline in net sales and profitability in June 2024, with net sales at 1,151.26 Cr, down from 1,229.62 Cr in June 2023, and profit after tax decreasing to 200.98 Cr from 229.47 Cr. Overall, the company faced challenges with reduced sales, profits, and asset values.

Procter & Gamble Health Ltd's latest Q2 FY26 results show a net profit increase of 7.54% year-on-year, but a sequential revenue decline of 4.08% raises concerns about demand sustainability. While operating margins improved significantly and return on equity remains strong, challenges in cash flow and working capital management suggest a mixed operational outlook.

As of October 6, 2025, the trend is mildly bullish due to daily moving averages and Bollinger Bands, but tempered by mildly bearish weekly MACD and KST indicators, suggesting a cautious bullish outlook.

P & G Health Ltd has shown fluctuating performance, with net sales decreasing from 1,229.62 Cr in June 2023 to 1,151.26 Cr in June 2024, alongside declines in profitability metrics such as profit after tax and earnings per share. Total assets and liabilities also decreased significantly in the same period.

As of 24-Sep, Procter & Gamble Health Ltd's stock price is 6,304.60, having increased by 0.31% recently. The stock has shown strong year-to-date performance with a 20.55% return, but faces concerns over long-term growth despite strong fundamentals and management efficiency.

As of 23-Sep, Procter & Gamble Health Ltd's stock price is 6,287.00, up 0.52% today but down 0.80% over the past week and 4.36% over the past month. Despite strong long-term performance with a year-to-date return of 20.21%, concerns about growth and valuation may be affecting short-term investor sentiment.

As of 22-Sep, Procter & Gamble Health Ltd's stock price is 6,268.85, down 1.18%. Despite strong year-to-date performance and positive management indicators, recent declines in investor participation and high valuation are contributing to its current price drop.

As of 19-Sep, Procter & Gamble Health Ltd's stock price is 6,337.50, up 1.38%, and has outperformed its sector and the Sensex over the past week. Despite strong fundamentals and a significant year-to-date gain, concerns about long-term growth and high valuation persist.

As of 18-Sep, Procter & Gamble Health Ltd's stock is priced at 6,251.20, down 1.24% today and has declined 1.36% over the last two days. Despite strong long-term returns, recent underperformance and concerns over growth and valuation are affecting investor sentiment.

As of 17-Sep, Procter & Gamble Health Ltd's stock price is 6,330.00, down 0.12% after a trend reversal. Despite a strong year-to-date return of 21.03% and high management efficiency, concerns about long-term growth and an expensive valuation persist.

As of 16-Sep, Procter & Gamble Health Ltd's stock price is 6,337.50, having increased by 1.06% recently and outperforming the BSE500 index over the past year with a return of 22.94%. Despite strong long-term performance and institutional interest, concerns about long-term growth and high valuation persist.

As of 15-Sep, Procter & Gamble Health Ltd's stock price is 6,271.10, reflecting a recent increase but mixed performance overall, with a year-to-date return of 19.91%. Despite short-term declines in trading volume and investor participation, the stock has strong long-term growth prospects, although concerns about modest sales growth and high valuation may affect investor sentiment.

As of 12-Sep, Procter & Gamble Health Ltd's stock price is at 6,245.35, down 1.81% today and 3.84% over the past week, reflecting concerns over long-term growth potential and high valuation metrics despite strong year-to-date performance. The stock's decline contrasts with a 1.48% increase in the broader market, indicating underperformance relative to its sector.

As of 11-Sep, Procter & Gamble Health Ltd's stock price is 6,360.50, reflecting a 0.59% increase. The stock has shown a trend reversal with rising investor participation, strong long-term performance, but concerns about valuation and poor long-term growth persist.